Transactional partner Oren Livne and senior associate Andrew Haupt have joined Baker McKenzie’s Corporate & Securities Practice Group in New York, bringing experience advising life sciences, consumer product, and technology companies.

Oren and Andrew come to Baker McKenzie as part of a team from Morgan Lewis that includes partners Randall Sunberg and Denis Segota, who joined the Firm on February 19.

Randy, who co-heads the Firm’s North America Life Sciences Practice commented, “Oren is a first-rate practitioner who provides our life sciences clients with key licensing and IP-related advice. Andrew's prior in-house experience will be a great asset for our clients. We’re thrilled that they have joined our growing team at Baker McKenzie.”  

Skilled in handling a variety of corporate matters, Oren has advised companies from startups to multinationals on complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, venture capital financings, mergers and acquisitions, and other intellectual property focused transactions. Before becoming an attorney, he co-founded a university technology transfer office and managed its licensing operations.  Andrew has represented life sciences companies in a similarly broad range of their legal affairs. Prior to private practice, Andrew was corporate counsel to a publicly traded biotechnology company. 

“The addition of Oren and the life sciences team demonstrates our commitment to building the healthcare practice with leading sector experts. With his industry and technology transfer knowledge, Oren has key expertise to assist companies in navigating this changing sector,” said Alan Zoccolillo, chair of Baker McKenzie's North America Healthcare Industry Group and chair of the Firm's North America Corporate & Securities Practice.

Baker McKenzie's Healthcare Industry group includes more than 500 lawyers worldwide who advise many of the world's largest pharmaceutical, biotech, medical device and healthcare services companies on a range of issues including transactional matters, patents and brands, global transfer pricing and tax planning strategies, product liability, competition and trade, commercial agreements, data privacy, employment issues and market entry. For the past five years, Baker McKenzie has ranked No. 1 for healthcare M&A by volume, completing more cross-border deals than any other law firm in the world, and is ranked by Chambers in the top 10 law firms in the world in life sciences.

“Oren is another excellent addition to our top-tier life sciences team. We look forward to working with him to grow our practice in this sector,” said Colin Murray, Baker McKenzie's North American Chief Executive Officer.

Oren added, "I’m excited to join Baker McKenzie’s team with Randy, Denis and Andrew. I look forward to working with my new colleagues as we expand the transactional services provided to clients.” 

Oren received his JD from New York University School of Law, where he has guest lectured on entrepreneurship. He earned his MBA, with distinction, from New York University’s Leonard N. Stern School of Business and his BS in biochemical engineering, with highest honors, from Rutgers University. Andrew received his JD from the University of Chicago Law School. He earned his AB, cum laude, Phi Beta Kappa, from Davidson College. 
Explore Our Newsroom